Progress in metastatic colorectal cancer: Growing role of cetuximab to optimize clinical outcome

Clinical and Translational Oncology

Volumn 12, Issue 8, 2010, Pages 533-542

  García Foncillas, Jesús ^a   Díaz Rubio, Eduardo ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b NONE

Author keywords

(MeSH terms): Cetuximab; Adjuvant; Antibodies; Chemotherapy; Colorectal neoplasms therapy; Epidermal growth factor; Monoclonal therapeutic use; Receptor

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CORTICOSTEROID; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; GEFITINIB; IRINOTECAN; K RAS PROTEIN; MAGNESIUM SULFATE; OXALIPLATIN; PANITUMUMAB; SUNITINIB; VATALANIB;

ACNE; ADJUVANT THERAPY; AIRWAY OBSTRUCTION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER ADJUVANT THERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; LIVER METASTASIS; LIVER RESECTION; LOW DRUG DOSE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NONHUMAN; ONCOGENE; ONCOGENE BRAF; ONCOGENE K RAS; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; URTICARIA;

ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL; VITAMIN B COMPLEX;

EID: 77958191989     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0551-3     Document Type: Review

References (130)

1. D.M. Parkin F. Bray J. Ferlay P. Pisani 2005 Global cancer statistics, 2002 CA Cancer J Clin 55 74 108 15761078 (Pubitemid 40372904)
2. National Comprehensive Cancer Network (2009) NCCN clinical practice guidelines in oncology™. Colon cancer. V.2.2009. Available at http://www.nccn.org
3. P. Boyle J. Ferlay 2005 Cancer incidence and mortality in Europe, 2004 Ann Oncol 16 481 488 1:STN:280:DC%2BD2M%2FptVGrsA%3D%3D 15718248 (Pubitemid 40458328)
4. M.M. Center A. Jemal E. Ward 2009 International trends in colorectal cancer incidence rates Cancer Epidemiol Biomarkers Prev 18 1688 1694 19505900
5. J. Ribes M. Navarro R. Cèries, et al. 2009 Colorectal cancer mortality in Spain: trends and projections for 1985-2019 Eur J Gastroenterol Hepatol 21 92 100 19011574
6. K. Field L. Lipton 2007 Metastatic colorectal cancer - past, progress and future World J Gastroenterol 13 3806 3815 1:CAS:528:DC%2BD2sXhtVSisb3L 17657834 (Pubitemid 47272305)
7. A. Jemal T. Murray E. Ward, et al. 2005 Cancer statistics, 2005 CA Cancer J Clin 55 10 30 15661684 (Pubitemid 40310185)
8. M.M. Borner 1999 Neoadjuvant chemotherapy for unresectable liver metastases of colorectal cancer - too good to be true? Ann Oncol 10 623 626 1:STN:280:DyaK1MzntVOksg%3D%3D 10442182
9. B. Kremeny 2006 Management of liver metastases from colorectal cancer Oncology 20 1161 1176
10. A. Muratore D. Zorzi H. Bouzari, et al. 2007 Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 14 766 770 17103261 (Pubitemid 46175325)
11. M.A. Hammoud I.E. McCutcheon R. Elsouki, et al. 1996 Colorectal carcinoma and brain metastasis: distribution, treatment, and survival Ann Surg Oncol 3 453 463 1:STN:280:DyaK2s%2FjtV2muw%3D%3D 8876887
12. S.R. Pestieau P.H. Sugarbaker 2000 Treatment of primary colon cancer with peritoneal carcinomatosis. Comparison of concomitant vs. delayed management Dis Colon Rectum 43 1341 1346 1:STN:280:DC%2BD3crgtl2muw%3D%3D 11052509
13. I. Chau M.J. Allen D. Cunningham, et al. 2004 The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer J Clin Oncol 22 1420 1429 1:CAS:528:DC%2BD2cXpt1yjurw%3D 15007086 (Pubitemid 41103624)
14. C.E. Desch A.B. Benson 3rd M.R. Somerfield, et al. 2005 Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guidelines J Clin Oncol 23 8512 8519 16260687 (Pubitemid 46260248)
15. B. Wiering W.V. Vogel T.J. Ruers W.J. Oyen 2008 Controversies in the management of colorectal liver metastases: role of PET and PET/CT Dig Surg 25 413 420 19212113
16. O.A. Ogunbiyi F.L. Flanagan F. Dehdashti, et al. 1997 Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography Ann Surg Oncol 4 613 620 1:STN:280: DyaK1c%2FnvVelsQ%3D%3D 9416407 (Pubitemid 127725488)
17. L.F. de Geus-Oei T.J. Ruers C.J. Punt, et al. 2006 FDG-PET in colorectal cancer Cancer Imaging 6 S71 S81 17114081
18. L.F. de Geus-Oei D. Vriens H.W. van Laarhoven, et al. 2009 Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review J Nucl Med 50 Suppl1 43S 54S 19403879
19. E. Tobaruela J.M. Enriquez M. Diez, et al. 1997 Evaluation of serum carcinoembryonic antigen monitoring in the follow-up of colorectal cancer patients with metastatic lymph nodes and a normal preoperative serum level Int J Biol Markers 12 18 21 1:STN:280:DyaK2szhvFyhtw%3D%3D 9176713 (Pubitemid 27229452)
20. W. Graboń M. Mielczarek-Puta A. Chrzanowskaa A. Barańczyk-Kuźma 2009 l-Arginine as a factor increasing arginase significance in diagnosis of primary and metastatic colorectal cancer Clin Biochem 42 353 357 19101531
21. P.H. Levine A. Joutovsky J. Cangiarella, et al. 2006 CDX-2 expression in pulmonary fineneedle aspiration specimens: a useful adjunct for the diagnosis of metastatic colorectal adenocarcinoma Diagn Cytopathol 34 191 195 16470859
22. H. Kelly R.M. Goldberg 2005 Systemic therapy for metastatic colorectal cancer: current options, current evidence J Clin Oncol 23 4553 4560 1:CAS:528:DC%2BD2MXnsl2ksLs%3D 16002847 (Pubitemid 46196586)
23. H.D. González J. Figueras 2007 Practical questions in liver metastases of colorectal cancer: general principles of treatment HPB (Oxford) 9 251 258 (Pubitemid 47263958)
24. S.M. Erturk T. Ichikawa H. Fujii, et al. 2006 PET imaging for evaluation of metastatic colorectal cancer of the liver Eur J Radiol 58 229 235 16457980
25. G. Nuzzo F. Giuliante F. Ardito, et al. 2008 Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience Surgery 143 384 393 18291260
26. P.C. Simmonds J.N. Primrose J.L. Colquitt, et al. 2006 Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies Br J Cancer 94 982 999 1:STN:280:DC%2BD287pt1altw%3D%3D 16538219
27. L. Viganò A. Ferrero R. Lo Tesoriere L. Capussotti 2008 Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity Ann Surg Oncol 15 2458 2464 18463927
28. C. Laurent A. Sa Cunha E. Rullier, et al. 2004 Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis J Am Coll Surg 198 884 891 15194069 (Pubitemid 38759838)
29. G. Masi F. Loupakis L. Pollina, et al. 2009 Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases Ann Surg 249 420 425 19247029
30. G. Masi S. Cupini L. Marcucci, et al. 2006 Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer Ann Surg Oncol 13 58 65 16372158 (Pubitemid 43117646)
31. L.S. Teng Y. Zheng J. Zhang 2008 Neoadjuvant chemotherapy for metastatic colorectal cancer to the liver: from chemotherapy to targeting therapy Hepatobiliary Pancreat Dis Int 6 569 570
32. T. Aloia M. Sebagh M. Plasse, et al. 2006 Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases J Clin Oncol 24 4983 4990 1:CAS:528:DC%2BD28Xht1GnurzI 17075116 (Pubitemid 46631400)
33. R.M. Goldberg M.L. Rothenberg E. Van Cutsem, et al. 2007 The continuum of care: a paradigm for the management of metastatic colorectal cancer Oncologist 12 38 50 17227899 (Pubitemid 46143501)
34. E. Van Cutsem P.M. Hoff P. Harper, et al. 2004 Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials Br J Cancer 90 1190 1197 15026800 (Pubitemid 38496812)
35. A. de Gramont A. Figer M. Seymour, et al. 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer J Clin Oncol 18 2938 2947 10944126 (Pubitemid 30644117)
36. H.S. Hochster L.L. Hart R.K. Ramanathan, et al. 2006 Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study J Clin Oncol 24 Suppl 3510
37. C. Fuchs J. Marshall E. Mitchell, et al. 2006 A randomized trial of first-line irinotecan/fluoropyrimidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C) J Clin Oncol 24 Suppl 3506
38. L.B. Saltz J.V. Cox C. Blanke, et al. 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer N Engl J Med 343 905 914 1:CAS:528:DC%2BD3cXntFOkt7Y%3D 11006366
39. J.Y. Douillard D. Cunningham A.D. Roth, et al. 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial Lancet 355 1041 1047 1:CAS:528:DC%2BD3cXisFOnsb4%3D 10744089 (Pubitemid 30162806)
40. C. Tournigand T. André E. Achille, et al. 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study J Clin Oncol 22 229 237 1:CAS:528:DC%2BD2cXpsVKit7w%3D 14657227 (Pubitemid 41095086)
41. R.M. Goldberg D.J. Sargent R.F. Morton, et al. 2004 A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J Clin Oncol 22 23 30 1:CAS:528:DC%2BD2cXpsVKitbY%3D 14665611
42. G. Colucci V. Gebbia G. Paoletti, et al. 2005 Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale J Clin Oncol 23 4866 4875 1:CAS:528:DC%2BD2MXpsFWmt7s%3D 15939922 (Pubitemid 46223991)
43. J. Souglakos N. Androulakis K. Syrigos, et al. 2006 FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) Br J Cancer 94 798 805 1:CAS:528: DC%2BD28Xis1GktL0%3D 16508637
44. H. Hurwitz L. Fehrenbacher W. Novotny, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 335 2342 (Pubitemid 38702844)
45. D. Cunningham Y. Humblet S. Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 1:CAS:528:DC%2BD2cXlvFGitbk%3D 15269313 (Pubitemid 38944402)
46. M.L. Rothenberg J.V. Cox C. Butts, et al. 2008 Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study Ann Oncol 19 1720 1726 1:STN:280: DC%2BD1cnhslOgug%3D%3D 18550577
47. J. Cassidy S. Clarke E. Díaz-Rubio, et al. 2008 Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer J Clin Oncol 26 2006 2012 1:CAS:528:DC%2BD1cXlvFaqs7s%3D 18421053
48. R. Porschen H.T. Arkenau S. Kubicka, et al. 2007 Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group J Clin Oncol 25 4217 4223 1:CAS:528:DC%2BD2sXhtFyis7vK 17548840 (Pubitemid 47548561)
49. E. Díaz-Rubio J. Tabernero A. Gómez-España, et al. 2007 Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial J Clin Oncol 25 4224 4230 17548839 (Pubitemid 47548562)
50. T. Delaunoit R.M. Goldberg D.J. Sargent, et al. 2004 Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin Cancer 101 2170 2176 1:CAS:528: DC%2BD2cXhtVKisbnP 15470715
51. R. Goldberg 2006 Therapy for metastatic colorectal cancer Oncologist 11 981 987 1:CAS:528:DC%2BD28XhtFOrsb3P 17030638 (Pubitemid 44564805)
52. D. Arnold R. Siewczynski H.J. Schmoll 2006 The integration of targeted agents into systemic therapy of metastatic colorectal cancer Ann Oncol 17 Suppl10 122 128 (Pubitemid 44541999)
53. C.H. Köhne H.J. Lenz 2009 Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer Oncologist 14 478 488 19411318
54. J. Rodriguez R. Zarate E. Bandres, et al. 2007 Combining chemotherapy and targeted therapies in metastatic colorectal cancer Word J Gastroenterol 13 5867 5876 1:CAS:528:DC%2BD2sXhsVGrt7nF (Pubitemid 350148503)
55. J.C. Lee N.H. Chow S.T. Wang S.M. Huang 2000 Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients Eur J Cancer 36 748 753 1:CAS:528:DC%2BD3cXitlKktLg%3D 10762747 (Pubitemid 30179746)
56. F. Kabbinavar H.I. Hurwitz L. Fehrenbacher, et al. 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 2 60 65
57. H.I. Hurwitz L. Fehrenbacher J.D. Hainsworth, et al. 2006 Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 3502 3508
58. B.J. Giantonio P.J. Catalano N.J. Meropol, et al. 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 1:CAS:528:DC%2BD2sXlsVyntbc%3D 17442997
59. L. Saltz S. Clarke E. Diaz-Rubio, et al. 2008 Bevacizumab (Bev) in combination with XELOX or FOLFOX4: updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer J Clin Oncol 26 2013 2019 1:CAS:528:DC%2BD1cXlvFaqs7g%3D 18421054
60. A. Sobrero S. Ackland S. Clarke, et al. 2009 Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer Oncology 77 113 119 1:CAS:528:DC%2BD1MXhtFSqtb7J 19628950
61. Van Cutsem E, Rivera F, Berry S.; et al.(2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. doi:10.1093/annonc/ mdp233
62. Y. Cao A. Tan F. Gao, et al. 2009 A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer Int J Colorectal Dis 24 677 695 19184059
63. I. Porebska A. Harlozińska T. Bojarowski 2000 Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas Tumor Biol 21 105 115 1:CAS:528:DC%2BD3cXit12lsL0%3D (Pubitemid 30114656)
64. Saltz I, Rubin M, Hochster H.; et al.(2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20. Abstract 7
65. D. Cunningham Y. Humblet S. Siena, et al. 2004 Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 337 345 1:CAS:528:DC%2BD2cXlvFGitbk%3D 15269313 (Pubitemid 38944402)
66. B. Vincenzi D. Santini C. Rabitti, et al. 2006 Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial Br J Cancer 94 792 797 1:CAS:528:DC%2BD28Xis1GktLs%3D 16508634
67. V. Gebbia S. Del Prete N. Borsellino, et al. 2006 Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience Clin Colorectal Cancer 5 422 428 16635281
68. A.F. Sobrero J. Maurel L. Fehrenbacher, et al. 2008 EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer J Clin Oncol 26 2311 2319 1:CAS:528:DC%2BD1cXntVOltrk%3D 18390971
69. H. Wilke R. Glynne-Jones J. Thaler, et al. 2008 Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL Study J Clin Oncol 26 5335 5343 1:CAS:528:DC%2BD1MXhslCmtA%3D%3D 18854570
70. G. Folprecht M.P. Lutz P. Schöffski, et al. 2006 Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma Ann Oncol 17 450 456 1:STN:280: DC%2BD287ht1Olug%3D%3D 16303861 (Pubitemid 43329582)
71. J.L. Raoul J.L. Van Laethem M. Peeters, et al. 2009 Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study BMC Cancer 9 112 19366444
72. D. Arnold T. Höhler C. Dittrich, et al. 2008 Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group Ann Oncol 19 1442 1449 1:STN:280:DC%2BD1cvotVOgtg%3D%3D 18441330
73. E. Van Cutsem C.H. Köhne E. Hitre, et al. 2009 Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 1408 1417 19339720
74. C. Bokemeyer I. Bondarenko A. Makhson, et al. 2009 Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 663 671 1:CAS:528:DC%2BD1MXjsVCjsrk%3D 19114683
75. E. Maiello F. Giuliani V. Gebbia, et al. 2007 Cetuximab: clinical results in colorectal cancer Ann Oncol 18 Suppl6 vi8 vi10 17591840
76. S.F. Wong 2005 Cetixumab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer Clin Ther 27 684 694 1:CAS:528:DC%2BD2MXnvF2rurw%3D 16117976 (Pubitemid 41583517)
77. D. Barnett A. Stevens C. Longson 2006 Appraisal of bevacizumab and cetuximab for treatment of metastatic colorectal cancer in the UK Lancet Oncol 7 807 808 17039634
78. M. Peeters T. Price J.L. Van Laethem 2009 Antiepidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today? Oncologist 14 29 39 1:CAS:528:DC%2BD1MXjt1Clt7g%3D 19144681
79. Z. Wainberg J.R. Hecht 2006 Panitumumab in colon cancer: a review and summary of ongoing trials Expert Opin Biol Ther 6 1229 1235 1:CAS:528: DC%2BD28XhtVyqtr7M 17049019 (Pubitemid 44714148)
80. M. Wu A. Rivkin T. Pham 2008 Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer Clin Ther 30 14 30 18343240 (Pubitemid 351843429)
81. S. Li K.R. Schmitz P.D. Jeffrey, et al. 2005 Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 301 311 1:CAS:528:DC%2BD2MXjvFSkurk%3D 15837620 (Pubitemid 40544648)
82. L.B. Saltz N.J. Meropol P.J. Loehrer Sr, et al. 2004 Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor N Engl J Med 343 905 914
83. H.J. Lenz E. Van Cutsem S. Khambata-Ford, et al. 2006 Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines J Clin Oncol 24 4914 4921 1:CAS:528:DC%2BD28Xht1eiu73K 17050875 (Pubitemid 46630920)
84. J. Souglakos A. Kalykaki L. Vamvakas, et al. 2007 Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy Ann Oncol 18 305 310 1:STN:280:DC%2BD2s%2Fotlaqsg%3D%3D 17079693 (Pubitemid 46323098)
85. H.F. Lenz 2007 Cetuximab in the management of colorectal cancer Biologics 1 77 91 1:CAS:528:DC%2BD1cXjsVCgtr0%3D 19707318
86. Jonker DJ, Karapetis CS, Moore M.; et al.(2007) Randomized phase III trial of cetuximab monotherapy plus best supportive care [BSC] versus BSC Alone in patients with pretreated metastatic epidermal growth factor receptor [EGFR]-positive colorectal carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and the Australasian Gastro-Intestinal Trials Group (AGITG). Proc Am Assoc Cancer Res. Abstract LB-1
87. Sobrero AF, Fehrenbacher L, Rivera F.; et al.(2007) Randomized phase III trial of cetuximab plus irinotecan versus irinotecan alone for metastatic colorectal cancer in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial. Proc Am Assoc Cancer Res. Abstract LB-2
88. Folprecht G, Gruenberger T, Hartmann JT.; et al.(2009) Cetuximab plus FOLFOX6 or cetuximab plus FOLFIRI as neoadjuvant treatment of nonresectable colorectal liver metastases: a randomized multicenter study (CELIM-study). 2009 ASCO Annual Meeting, Gastrointestinal Cancers Symposium. Abstract 296
89. Bechstein WO, Lang H, Köhne C.; et al.(2009) Resectability and agreement between surgeons: Review of CT and MR scan of the CELIM study: (Multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in unresectable liver metastases. J Clin Oncol 27:15 (Suppl). Abstract 4091.
90. T. Macarulla J. Ramos E. Élez J. Capdevila, et al. 2008 Update on novel strategies to optimize cetuximab therapy in patients with metastatic colorectal cancer Clin Colorectal Cancer 7 300 308 1:CAS:528: DC%2BD1cXht1enu7%2FI 18794061
91. L.B. Saltz H.J. Lenz H.L. Kindler, et al. 2007 Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study J Clin Oncol 25 4557 4561 1:CAS:528:DC%2BD2sXht1yhsr%2FM 17876013
92. J. Tol M. Koopman A. Cats, et al. 2009 Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 563 572 1:CAS:528:DC%2BD1MXhsFyitrw%3D 19196673
93. L. Simi N. Prateso M. Vignoli, et al. 2008 High resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer Am J Clin Pathol 130 247 253 1:CAS:528:DC%2BD1cXhtVegtbnM 18628094
94. S. Khambata-Ford C.R. Garrett N.J. Meropol, et al. 2007 Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab J Clin Oncol 25 3230 3237 1:CAS:528:DC%2BD2sXhtVWqs7rF 17664471 (Pubitemid 47325606)
95. J.H. van Krieken A. Jung T. Kirchner, et al. 2008 KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program Virchow Arch 453 417 431
96. H. Linardou I.J. Dahabreh D. Kanaloupiti, et al. 2008 Assessment of somatic K-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 962 972 1:CAS:528:DC%2BD1cXhtFOmurvJ 18804418
97. R.G. Amado M. Wolf M. Peeters, et al. 2008 Wildtype KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 1626 1634 1:CAS:528:DC%2BD1cXltlWhsrw%3D 18316791
98. A. Lièvre J.B. Bachet V. Boige, et al. 2008 KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Cin Oncol 26 374 379 (Pubitemid 351171687)
99. S. Benvenuti A. Sartore-Bianchi F. Di Nicolantonio, et al. 2007 Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies Cancer Res 67 2643 2648 1:CAS:528:DC%2BD2sXivV2ns7w%3D 17363584 (Pubitemid 46548951)
100. W. De Roock H. Piessevaux J. De Schutter, et al. 2008 KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab Ann Oncol 19 508 515 17998284 (Pubitemid 351325672)
101. G. Finocchiaro F. Cappuzzo P.A. Jänne, et al. 2007 EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer J Clin Oncol 2007 ASCO Annual Meeting Proceedings 25 Suppl 4021
102. F. Di Fiore F. Blanchard F. Charbonnier, et al. 2007 Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy Br J Cancer 23 1166 1169 (Pubitemid 46625066)
103. A. Lièvre J.B. Bachet D. Le Corre, et al. 2006 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 3992 3995 16618717
104. Cervantes A, Macarulla T, Martinelli E.; et al.(2008) Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 26(Suppl). Abstract 4129
105. Van Cutsem E, Lang I, D'haens G.; et al.(2008) KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26(Suppl). Abstract 2
106. C.S. Karapetis S. Khambata-Ford D.J. Jonker, et al. 2008 K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 1757 1765 1:CAS:528:DC%2BD1cXht12nu77J 18946061
107. Bokemeyer C, Bondarenko I, Hartmann JT.; et al.(2008) KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 26(Suppl). Abstract 4000
108. Punt CJ, Tol J, Rodenburg CJ.; et al.(2008) Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol 26(Suppl). Abstract LBA4011 (Pubitemid 351461045)
109. E. Winer J. Gralow L. Diller, et al. 2009 Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology J Clin Oncol 27 812 816 19103723
110. C.J. Allegra J.M. Jessup M.R. Somerfield, et al. 2009 American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to antiepidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 2091 2096 19188670
111. National Comprehensive Cancer Network (2010) NCCN clinical practice guidelines in colon/rectal cancer. http://www.nccn.org/professionals/physician- gls/f-guidelines.asp Accessed March 8, 2010
112. M. Schlaeth S. Berger S. Derer K. Klausz S. Lohse M. Dechant, et al. 2010 Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells Cancer Sci 101 1080 1088 1:CAS:528:DC%2BC3cXmsF2qtL0%3D 20331636
113. F. Bibeau E. Lopez-Crapez F. Di Fiore, et al. 2009 Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan J Clin Oncol 27 1122 1129 1:CAS:528:DC%2BD1MXktVCisr8%3D 19164213
114. Van Cutsem E, Lang I, Folprecht G.; et al.(2010) Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL trial. ASCO 2010. Gastrointestinal Cancers Symposium. Abstract 281
115. Bokemeyer C, Bondarenko I, Hartmann JT.; et al.(2010) Biomarkers predictive for outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line FOFOX4 plus or minus cetuximab: updated data from the OPUS study. ASCO 2010. Gastrointestinal Cancers Symposium. Abstract 428
116. Kohne C, Rougier P, Stroh C.; et al.(2010) Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): a meta-analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. ASCO 2010. Gastrointestinal Cancers Symposium. Abstract 406
117. Tsiatis AC, Norris-Kirby A, Rich RG.; et al.(2009) Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations. Diagnostic and clinical implications. J Mol Diagn doi:10.2353/jmoldx.2010.090188
118. W. Weichert C. Schewe A. Lehmann, et al. 2010 KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology J Mol Diagn 12 35 42 1:CAS:528: DC%2BC3cXhslWmsL4%3D 20007841
119. Z. Zuo S.S. Chen P.K. Chandra, et al. 2009 Application of COLD-PCR for improved detection of KRAS mutations in clinical samples Mod Pathol 22 1023 1031 1:CAS:528:DC%2BD1MXpsVKns7g%3D 19430420
120. W.A. Franklin J. Haney M. Sugita 2010 KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer J Mol Diagn 12 43 50 1:CAS:528:DC%2BC3cXhslWmsLw%3D 20007845
121. X. Su M.E. Lacouture Y. Jia S. Wu 2009 Risk of high-grade skin rash in cancer patients treated with cetuximab-an antibody against epidermal growth factor receptor: systemic review and metaanalysis Oncology 77 124 133 1:CAS:528:DC%2BD1MXhtFSqtb7L 19622903
122. J. Bernier J. Bonner J.B. Vermorken, et al. 2008 Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy and EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck Ann Oncol 19 142 149 1:STN:280:DC%2BD1c%2FgtVahsw%3D%3D 17785763
123. Folprecht G, Nowacki M, Lang I.; et al.(2009) Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): a quality-of-life (QoL) analysis of the CRYSTAL trial. J Clin Oncol 27:15s (Suppl). Abstract 4076
124. Siena S, Glynne-Jones R, Thaler J.; et al.(2007) MABEL - A large multinational study of cetuximab plus irinotecan in irinotecan-resistant metastatic colorectal cancer: Update on infusion related reactions (IRR). ASCO 2007. Gastrointestinal Cancers Symposium. Abstract 353
125. M.G. Fakih G. Wilding J. Lombardo 2006 Cetuximab-induced hypomagnesemia in patients with colorectal cancer Clin Colorectal Cancer 6 152 156 1:CAS:528:DC%2BD28XhtVWrsrjF 16945172 (Pubitemid 44445751)
126. B. Vincenzi D. Santini S. Galluzzo, et al. 2008 Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of early efficacy and outcome Clin Cancer Res 14 4219 1:CAS:528:DC%2BD1cXnvFyksrY%3D 18594003
127. H.J. Au C.S. Karapetis C.J. O'Callaghan, et al. 2009 Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial J Clin Oncol 27 1822 1828 1:CAS:528:DC%2BD1MXltlSisLg%3D 19273701
128. R.K. Ramanathan 2008 Alternative dosing schedules for cetuximab: a role for biweekly administration? Clin Colorectal Cancer 7 364 368 1:CAS:528:DC%2BD1MXmsVWlug%3D%3D 19036688
129. H. Mrabti C. De la Fouchardiere F. Desseigne, et al. 2009 Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer J Cancer Res Ther 5 272 276 1:CAS:528: DC%2BC3cXkvVyhtr4%3D 20160361
130. J. Tabernero P. Pfeiffer A. Cervantes 2008 Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 13 113 119 1:CAS:528:DC%2BD1cXktVSgsrY%3D 18305055 (Pubitemid 351342574)